Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Jazz Pharmaceuticals Released Topline Results From Phase 3 HERIZON-GEA-01 Trial Of Ziihera (Zanidatamab-hrii) In Combination With Chemotherapy, With Or Without Tevimbra (Tislelizumab) For Untreated HER2+ Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma

Author: Benzinga Newsdesk | November 17, 2025 06:11am
Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward
  • Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first OS interim analysis
  • Ziihera plus the PD-1 inhibitor Tevimbra (tislelizumab) and chemotherapy demonstrated clinically meaningful and statistically significant improvements in OS and PFS versus trastuzumab and chemotherapy
  • Company plans to submit a supplemental BLA for this indication in first half of 2026

Posted In: JAZZ ONC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist